The acute effect of tropisetron on ECG parameters in cancer patients

Basit Öğe Kaydı
dc.contributor.authorYavas, Ozlem
dc.contributor.authorYazici, Mehmet
dc.contributor.authorEren, Onder
dc.contributor.authorBoruban, Cem
dc.contributor.authorArtac, Mehmet
dc.contributor.authorGenc, Mine
dc.date.accessioned2020-03-26T17:27:58Z
dc.date.available2020-03-26T17:27:58Z
dc.date.issued2008
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractObjectives The 5-hydroxytryptamine 3 receptor antagonists, including tropisetron, ondansetron, granisetron, and dolasetron are agents used effectively for supportive care. They are used for the prevention and treatment of chemotherapy and radiotherapy-induced emesis. Despite their overall excellent safety profile, some electrocardiographic changes related to heart rate and repolarization were reported. Ondansetron, granisetron, and dolasetron were studied on this manner. But to our knowledge, there is no information about the cardiac side effects of tropisetron. In this study, we aimed to determine the acute effects of tropisetron on ECG parameters related to repolarization, heart rate, and systemic blood pressure. Materials and methods Fifty-five cancer patients who received tropisetron for the prevention of acute chemotherapy-induced nausea and vomiting were enrolled into this single center, prospective study. Standard 12-lead ECG recordings were performed at baseline and 30 min after tropisetron (5 mg given over 1 min IV bolus) administration. P wave durations and corrected QT intervals were measured; P wave dispersion and QTc dispersion were calculated. Results In comparison with baseline, mean heart rate significantly decreased 30 min after administration of tropisetron. Tropisetron did not result in a significant change in P wave duration, corrected QT interval, P dispersion, and QTc dispersion. Conclusion In this study, tropisetron did not show any ventricular and atrial arrhythmogenic effect because of repolarization abnormalities. Only it may cause a slight decrease in heart rate.en_US
dc.identifier.doi10.1007/s00520-007-0400-2en_US
dc.identifier.endpage1015en_US
dc.identifier.issn0941-4355en_US
dc.identifier.issue9en_US
dc.identifier.pmid18239945en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage1011en_US
dc.identifier.urihttps://dx.doi.org/10.1007/s00520-007-0400-2
dc.identifier.urihttps://hdl.handle.net/20.500.12395/22685
dc.identifier.volume16en_US
dc.identifier.wosWOS:000258286500005en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSPRINGERen_US
dc.relation.ispartofSUPPORTIVE CARE IN CANCERen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjecttropisetronen_US
dc.subjectcardiotoxicityen_US
dc.subject5-HT(3) receptor antagonisten_US
dc.subjectECGen_US
dc.titleThe acute effect of tropisetron on ECG parameters in cancer patientsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu